Studies on cell-mediated immunity in women using different fertility regulating methods.
Cell-mediated immunity (CMI) was assessed in women using fertility regulating methods for 1-5 months, 6-11 months or 12-18 months. The CMI as assessed by phytohaemagglutin in (PHA)-induced lymphocyte transformation of treated groups were compared with that of normal subjects who were not using any contraceptive methods and women on conventional methods of contraception. The data obtained indicates that there is no significant alteration of CMI in women fitted with IUCD or women on estrogen progestogen combination. However, a significant suppression of CMI is observed in women in progestogen pills for 12-18 months. The short term therapy did not affect the CMI. In a prospective study it was found that the CMI in women before and after the use of combination therapy for 1-5 and 6-11 months revealed no change. Estradiol and progesterone at concentration on 1 microgram/ml in culture medium suppressed PHA-induced lymphocyte transformation.
D000293:Adolescent; D000328:Adult; D003267:Contraception; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007435:Intrauterine Devices, Copper; D008213:Lymphocyte Activation; D009640:Norethindrone; D009644:Norgestrel; D010835:Phytohemagglutinins / Q000494:pharmacology; D013997:Time Factors
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D010835:Phytohemagglutinins; D009644:Norgestrel; D004997:Ethinyl Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; D009640:Norethindrone